Podcast Pearls
Overcoming Acquired Resistance With Second-Generation TRK Inhibitors

Download this short summary slideset based on the content from a CCO podcast covering key data on second-generation TRK inhibitors that can overcome resistance to first-generation agents in patients with NTRK fusion–positive solid tumors.
George D. Demetri, MD
Alexander Drilon, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 260 KB
Released: November 9, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bayer HealthCare Pharmaceuticals Inc.

Related Content

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for gastroesophageal cancers

Manish A. Shah, MD Released: January 21, 2022

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for pancreatic and biliary tract cancers

Rachna Shroff, MD Released: January 21, 2022

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for colorectal cancer (CRC)

John L. Marshall, MD Released: January 21, 2022

In this commentary from Clinical Care Options (CCO), Asim V. Farooq, MD and Joann Kang, MD, provide guidance on monitoring and mitigating ocular toxicities associated with antibody-drug conjugates

Asim V. Farooq, MD Joann Kang, MD Released: January 20, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings